PRECISION BIOSCIENCES INC

Precision BioSciences boosts senior leadership with 20,979 RSUs per exec, tying pay to future success and signaling confidence amid a 15% share dip.

Precision BioSciences insiders buy RSUs, signaling confidence amid a price dip and hinting at future upside from upcoming clinical milestones.

Precision BioSciences insider activity shows routine RSU vesting, while CTX‑001’s Phase III safety data and FDA fast‑track status offer promising gene‑editing prospects for clinicians and investors.

Precision BioSciences insider activity shows CEO RSU vesting and leadership buying, aligning long‑term value with CRISPR‑based therapy progress and FDA Fast‑Track milestones.